IBDEI2QK ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,45911,1,4,0)
 ;;=4^G31.89
 ;;^UTILITY(U,$J,358.3,45911,2)
 ;;=^5003814
 ;;^UTILITY(U,$J,358.3,45912,0)
 ;;=G20.^^203^2265^19
 ;;^UTILITY(U,$J,358.3,45912,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,45912,1,3,0)
 ;;=3^Parkinson's Disease
 ;;^UTILITY(U,$J,358.3,45912,1,4,0)
 ;;=4^G20.
 ;;^UTILITY(U,$J,358.3,45912,2)
 ;;=^5003770
 ;;^UTILITY(U,$J,358.3,45913,0)
 ;;=G10.^^203^2265^12
 ;;^UTILITY(U,$J,358.3,45913,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,45913,1,3,0)
 ;;=3^Huntington's Disease
 ;;^UTILITY(U,$J,358.3,45913,1,4,0)
 ;;=4^G10.
 ;;^UTILITY(U,$J,358.3,45913,2)
 ;;=^5003751
 ;;^UTILITY(U,$J,358.3,45914,0)
 ;;=G12.21^^203^2265^1
 ;;^UTILITY(U,$J,358.3,45914,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,45914,1,3,0)
 ;;=3^Amyotrophic Lateral Sclerosis
 ;;^UTILITY(U,$J,358.3,45914,1,4,0)
 ;;=4^G12.21
 ;;^UTILITY(U,$J,358.3,45914,2)
 ;;=^6639
 ;;^UTILITY(U,$J,358.3,45915,0)
 ;;=G35.^^203^2265^18
 ;;^UTILITY(U,$J,358.3,45915,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,45915,1,3,0)
 ;;=3^Multiple Sclerosis
 ;;^UTILITY(U,$J,358.3,45915,1,4,0)
 ;;=4^G35.
 ;;^UTILITY(U,$J,358.3,45915,2)
 ;;=^79761
 ;;^UTILITY(U,$J,358.3,45916,0)
 ;;=G81.90^^203^2265^11
 ;;^UTILITY(U,$J,358.3,45916,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,45916,1,3,0)
 ;;=3^Hemiplegia,Unspec Side
 ;;^UTILITY(U,$J,358.3,45916,1,4,0)
 ;;=4^G81.90
 ;;^UTILITY(U,$J,358.3,45916,2)
 ;;=^5004120
 ;;^UTILITY(U,$J,358.3,45917,0)
 ;;=G81.91^^203^2265^9
 ;;^UTILITY(U,$J,358.3,45917,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,45917,1,3,0)
 ;;=3^Hemiplegia,Right Dominant Side
 ;;^UTILITY(U,$J,358.3,45917,1,4,0)
 ;;=4^G81.91
 ;;^UTILITY(U,$J,358.3,45917,2)
 ;;=^5004121
 ;;^UTILITY(U,$J,358.3,45918,0)
 ;;=G81.92^^203^2265^7
 ;;^UTILITY(U,$J,358.3,45918,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,45918,1,3,0)
 ;;=3^Hemiplegia,Left Dominant Side
 ;;^UTILITY(U,$J,358.3,45918,1,4,0)
 ;;=4^G81.92
 ;;^UTILITY(U,$J,358.3,45918,2)
 ;;=^5004122
 ;;^UTILITY(U,$J,358.3,45919,0)
 ;;=G81.93^^203^2265^10
 ;;^UTILITY(U,$J,358.3,45919,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,45919,1,3,0)
 ;;=3^Hemiplegia,Right Nondominant Side
 ;;^UTILITY(U,$J,358.3,45919,1,4,0)
 ;;=4^G81.93
 ;;^UTILITY(U,$J,358.3,45919,2)
 ;;=^5004123
 ;;^UTILITY(U,$J,358.3,45920,0)
 ;;=G81.94^^203^2265^8
 ;;^UTILITY(U,$J,358.3,45920,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,45920,1,3,0)
 ;;=3^Hemiplegia,Left Nondominant side
 ;;^UTILITY(U,$J,358.3,45920,1,4,0)
 ;;=4^G81.94
 ;;^UTILITY(U,$J,358.3,45920,2)
 ;;=^5004124
 ;;^UTILITY(U,$J,358.3,45921,0)
 ;;=G61.0^^203^2265^5
 ;;^UTILITY(U,$J,358.3,45921,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,45921,1,3,0)
 ;;=3^Guillain-Barre Syndrome
 ;;^UTILITY(U,$J,358.3,45921,1,4,0)
 ;;=4^G61.0
 ;;^UTILITY(U,$J,358.3,45921,2)
 ;;=^53405
 ;;^UTILITY(U,$J,358.3,45922,0)
 ;;=I67.9^^203^2265^4
 ;;^UTILITY(U,$J,358.3,45922,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,45922,1,3,0)
 ;;=3^Cerebrovascular Disease,Unspec
 ;;^UTILITY(U,$J,358.3,45922,1,4,0)
 ;;=4^I67.9
 ;;^UTILITY(U,$J,358.3,45922,2)
 ;;=^5007389
 ;;^UTILITY(U,$J,358.3,45923,0)
 ;;=I69.959^^203^2265^17
 ;;^UTILITY(U,$J,358.3,45923,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,45923,1,3,0)
 ;;=3^Late Eff of Stroke,Hemiplegia,Unspec Side
 ;;^UTILITY(U,$J,358.3,45923,1,4,0)
 ;;=4^I69.959
 ;;^UTILITY(U,$J,358.3,45923,2)
 ;;=^5007563
 ;;^UTILITY(U,$J,358.3,45924,0)
 ;;=I69.951^^203^2265^15
 ;;^UTILITY(U,$J,358.3,45924,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,45924,1,3,0)
 ;;=3^Late Eff of Stroke,Hemiplegia,Right Dominant Side
 ;;^UTILITY(U,$J,358.3,45924,1,4,0)
 ;;=4^I69.951
